Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people while warning that it’s far from clear how well the technology works.
The U.S. Food and Drug Administration (FDA) endorsed a blood test designed to spot early signs of dozens of cancers despite concerns about how definitive the test’s results may be, the Associated ...
The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3, 2026. Under that agreement, Kala markets and distributes Virotek's genetic ...
Grail’s Galleri test costs $1,000 and promises comprehensive early-stage screening for more than 50 types of cancer.
The test means patients can start treatment sooner and are spared weeks of uncertainty.
A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and ...
Federal health advisers have backed a blood test designed to detect signals associated with more than 50 types of cancer, but experts cautioned Wednesday that major questions remain about how ...
FDA panel backs first multi-cancer blood test, Galleri, confirming safety and recommending continued routine screenings for adults 50 and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results